Low Rates of Breakthrough COVID-19 Infection after SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease

Kimberly N. Weaver*, Xian Zhang, Xiangfeng Dai, Wenli Chen, Runa Watkins, Jeremy Adler, Marla C. Dubinsky, Arthur Kastl, Athos Bousvaros, Jennifer A. Strople, Raymond K. Cross, Peter D.R. Higgins, Ryan C. Ungaro, Meenakshi Bewtra, Emanuelle Bellaguarda, Francis A. Farraye, Riley Bs Craig, Cristian Hernandez, Margie E. Boccieri, Ann FirestineKelly Y. Chun, Millie D. Long, Michael D. Kappelman

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

We demonstrate low rates of breakthrough coronavirus disease 2019 (COVID-19) infection and mild course of illness following severe acute respiratory syndrome coronavirus 2 vaccination in a large cohort of inflammatory bowel disease patients. Residence in southern United States and lower median anti-receptor binding antibody level were associated with development of COVID-19.

Original languageEnglish (US)
Pages (from-to)483-486
Number of pages4
JournalInflammatory bowel diseases
Volume29
Issue number3
DOIs
StatePublished - Mar 1 2023

ASJC Scopus subject areas

  • Gastroenterology
  • Immunology and Allergy

Fingerprint

Dive into the research topics of 'Low Rates of Breakthrough COVID-19 Infection after SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease'. Together they form a unique fingerprint.

Cite this